Restoration Anatomic Acetabular Shell Revision Study
Launched by STRYKER ORTHOPAEDICS · Oct 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Restoration Anatomic Acetabular Shell Revision Study is looking into how well a specific hip implant works for patients who have had a previous hip surgery that didn't succeed. This study will follow people both from the past and going forward to see how long the new implant lasts and how well it helps with their hip problems, like arthritis. The study is currently recruiting participants of all ages and genders who meet certain criteria.
To join this study, participants need to be having a revision surgery for their failed hip implant and must be in good enough health to handle the procedure. They should be willing to attend follow-up appointments to monitor their recovery. However, people with certain health issues, such as severe obesity, active infections, or specific bone or systemic diseases, may not qualify. If eligible, participants can expect close monitoring of their recovery and the performance of the new implant.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is a candidate for a revision of a failed acetabular component with the Restoration Anatomic Acetabular Shell.
- • Subject has signed an IRB-approved, study specific Informed Consent Form (ICF).
- • Subject is skeletally mature.
- • Subject is a male or non-pregnant female.
- • Subject is willing and able to comply with postoperative scheduled clinical evaluations.
- Exclusion Criteria:
- • Subject has a non-Stryker retained stem at the time of study device implantation.
- • Subject has a Body Mass Index (BMI) \> 45.
- • Subject has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.
- • Subject has a mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.
- • Subject has compromised bone stock which cannot provide adequate support and/or fixation to the prosthesis.
- • Subject is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.
- • Subject is immunologically suppressed or receiving steroids in an excess of normal physiological requirements (e.g. \> 30 days).
- • Subject has a known sensitivity to device materials.
- • Subject is a prisoner.
About Stryker Orthopaedics
Stryker Orthopaedics, a division of Stryker Corporation, is a leading global medical technology company specializing in innovative orthopedic solutions. Committed to enhancing patient outcomes and advancing surgical techniques, Stryker Orthopaedics focuses on the development of cutting-edge devices and implants for joint replacement, trauma, and spinal surgery. Through rigorous clinical trials and research initiatives, Stryker Orthopaedics aims to deliver high-quality products that improve the quality of life for patients while supporting healthcare professionals with reliable, effective tools for surgical excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials